Baricitinib bersama remdesivir pendek masa pesakit pulih gan Adnan, Ahmad Suhael

Cael y testun llawn

Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa gan Jo, Y, Jamieson, L, Edoka, I, Long, L, Silal, S, Pulliam, JRC, Moultrie, H, Sanne, I, Meyer-Rath, G, Nichols, BE

“...<p><strong> Background</strong></p> Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown. ...”

Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir gan Chan, Yi-Hao, Young, Barnaby Edward, Fong, Siew-Wai, Ding, Ying, Goh, Yun Shan, Chee, Rhonda Sin-Ling, Tan, Seow-Yen, Kalimuddin, Shirin, Tambyah, Paul A., Leo, Yee Sin, Ng, Lisa F. P., Lye, David C., Renia, Laurent

Pynciau: Cael y testun llawn

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report gan Buckland, MS, Galloway, JB, Fhogartaigh, CN, Meredith, L, Provine, NM, Bloor, S, Ogbe, A, Zelek, WM, Smielewska, A, Yakovleva, A, Mann, T, Bergamaschi, L, Turner, L, Mescia, F, Toonen, EJM, Hackstein, C-P, Akther, HD, Vieira, VA, Ceron-Gutierrez, L, Periselneris, J, Kiani-Alikhan, S, Grigoriadou, S, Vaghela, D, Lear, SE, Török, ME, Hamilton, WL, Stockton, J, Quick, J, Nelson, P, Hunter, M, Coulter, TI, Devlin, L, CITIID-NIHR COVID-19 BioResource Collaboration, MRC-Toxicology Unit COVID-19 Consortium, Bradley, JR, Smith, KGC, Ouwehand, WH, Estcourt, L, Harvala, H, Roberts, DJ, Wilkinson, IB, Screaton, N, Loman, N, Doffinger, R, Lyons, PA, Morgan, BP, Goodfellow, IG, Klenerman, P, Lehner, PJ, Matheson, NJ

“...Here we report the use of remdesivir in a patient with COVID-19 and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia (XLA). ...”

Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality gan Olender, Susan A., Walunas, Theresa L., Martinez, Esteban, Perez, Katherine K., Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G., De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M., Lye, David C., Gottlieb, Robert L., Haubrich, Richard H., Chokkalingam, Anand P., Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M., Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O., Bernardino, Jose I., Boffito, Marta

Pynciau: Cael y testun llawn

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. gan Wang, Y, Zhang, D, Du, G, Du, R, Zhao, J, Jin, Y, Fu, S, Gao, L, Cheng, Z, Lu, Q, Hu, Y, Luo, G, Wang, K, Lu, Y, Li, H, Wang, S, Ruan, S, Yang, C, Mei, C, Wang, Y, Ding, D, Wu, F, Tang, X, Ye, X, Ye, Y, Liu, B, Yang, J, Yin, W, Wang, A, Fan, G, Zhou, F, Liu, Z, Gu, X, Xu, J, Shang, L, Zhang, Y, Cao, L, Guo, T, Wan, Y, Qin, H, Jiang, Y, Jaki, T, Hayden, FG, Horby, PW, Cao, B, Wang, C

“...Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. ...”

Remdesivir therapy for severe pediatric COVID-19 in Singapore: a single-center retrospective observational cohort study gan Seah, Valerie Xue Fen, Ong, Rina Yue Ling, Kam, Kai-Qian, Thoon, Koh Cheng, Tan, Natalie Woon Hui, Li, Jiahui, Nadua, Karen Donceras, Chong, Chia Yin, Yung, Chee Fu

“...There is a paucity of information on remdesivir (RDV) use in severe pediatric coronavirus disease 2019 (COVID-19). ...”
Cael y testun llawn

The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing intensive care unit capacity gan Nichols, BE, Jamieson, L, Zhang, SRC, Rao, GA, Silal, S, Pulliam, JRC, Sanne, I, Meyer-Rath, G

“...Countries such as South Africa have limited intensive care unit (ICU) capacity to handle the expected number of patients with COVID-19 requiring ICU care. Remdesivir can prevent deaths in countries such as South Africa by decreasing the number of days people spend in ICU, therefore freeing up ICU bed capacity....”

Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV) gan Jittamala, P, Schilling, WHK, Watson, JA, Luvira, V, Siripoon, T, Ngamprasertchai, T, Almeida, PJ, Ekkapongpisit, M, Cruz, C, Callery, JJ, Boyd, S, Anunsittichai, O, Hongsuwan, M, Singhaboot, Y, Pagornrat, W, Tuntipaiboontana, R, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Keayarsa, S, Madmanee, W, Aguiar, RS, Santos, FM, Batty, EM, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Sookprome, S, Poovorawan, K, Imwong, M, Taylor, WRJ, Chotivanich, V, Sangketchon, C, Ruksakul, W, Chotivanich, K, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ

“...<strong>Background<br></strong> Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus disease 2019 (COVID-19) has resulted in varying treatment guidelines. ...”

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir gan Singh, K, Rubenstein, K, Callier, V, Shaw-Saliba, K, Rupert, A, Dewar, R, Laverdure, S, Highbarger, H, Lallemand, P, Huang, M-L, Jerome, KR, Sampoleo, R, Mills, MG, Greninger, AL, Juneja, K, Porter, D, Benson, CA, Dempsey, W, El Sahly, HM, Focht, C, Jilg, N, Paules, CI, Rapaka, RR, Uyeki, TM, Clifford Lane, H, Beigel, J, Dodd, LE, Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members

Pynciau: “...antiviral efficacy, clinical trial, COVID-19, remdesivir, SARS-CoV-2...”

Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: a propensity score adjusted retrospective cohort study gan Koh, Lin Pin, Chua, Siang Li, Vasoo, Shawn, Toh, Matthias Paul Han Sim, Cutter, Jeremy Nicholas, Nah, Puay Hoon, Leo, Yee Sin, Tay, Jun Xin, Young, Barnaby Edward, Lye, David C., Ong, Sean W. X.

“...In this retrospective cohort study, we studied the effect of early use of sotrovimab and remdesivir in high-risk hospitalized COVID-19 patients. ...”
Cael y testun llawn

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial gan Monaghan, K, Wang, Y, Zhou, F, Zhang, D, Zhao, J, Du, R, Hu, Y, Cheng, Z, Gao, L, Jin, Y, Luo, G, Fu, S, Lu, Q, Du, G, Wang, K, Lu, Y, Fan, G, Zhang, Y, Liu, Y, Ruan, S, Liu, W, Jaki. T, Hayden, FG, Horby, PW, Cao, B, Wang, C

“...There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. ...”

A living WHO guideline on drugs for covid-19 gan Rochwerg, B, Agoritsas, T, Lamontagne, FCC, Leo, Y-S, Macdonald, H, Agarwal, A, Zeng, L, Lytvyn, L, Appiah, JA, Amin, W, Arabi, Y, Blumberg, L, Burhan, E, Bausch, F, Calfee, CS, Cao, B, Cecconi, M, Chanda, D, Cooke, G, Dunning, J, Du, B, Geduld, H, Gee, P, Hashimi, M, Hui, DS, Kabra, S, Kanda, S, Kawano-Dourado, L, Kim, Y-J, Kissoon, N, Kwizera, A, Laake, JH, Machado, FR, Mahaka, I, Manai, H, Mino, G, Nsutebu, E, Pshenichnaya, N, Qadir, N, Sabzwari, S, Sarin, R, Sharland, M, Shen, Y, Ranganathan, SS, Souza, J, Ugarte, S, Venkatapuam, S, Dat, VQ, Vuyiseka, D, Wuewickrama, A

“...New recommendation The latest version of this WHO living guidance focuses on remdesivir, following the 15 October 2020 preprint publication of results from the WHO SOLIDARITY trial. ...”

Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity trial results gan Pan, H, Peto, R, Henao-Restrepo, A-M, Preziosi, M-P, Sathiyamoorthy, V, Abdool Karim, Q, Alejandria, MM, Hernández García, C, Kieny, M-P, Malekzadeh, R, Murthy, S, Reddy, KS, Roses Periago, M, Abi Hanna, P, Ader, F, Al-Bader, AM, Alhasawi, A, Allum, E, Alotaibi, A, Alvarez-Moreno, CA, Appadoo, S, Asiri, A, Aukrust, P, Barratt-Due, A, Bellani, S, Branca, M, Cappel-Porter, HBC, Cerrato, N, Chow, TS, Como, N, Eustace, J, García, PJ, Godbole, S, Gotuzzo, E, Griskevicius, L, Hamra, R, Hassan, M, Hassany, M, Hutton, D, Irmansyah, I, Jancoriene, L, Kirwan, J, Kumar, S, Lennon, P, Lopardo, G, Lydon, P, Magrini, N, Maguire, T, Manevska, S, WHO Solidarity Trial Consortium

“...<p><strong>BACKGROUND:</strong> World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19)....”

The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme gan Walker, AP, Fan, H, Keown, JR, Knight, ML, Grimes, JM, Fodor, E

“...We further show that the nsp12 NiRAN (nidovirus RdRp-associated nucleotidyltransferase) domain performs this reaction, and can be inhibited by remdesivir triphosphate, the active form of the antiviral drug remdesivir. ...”

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK gan Shields, AM, Anantharachagan, A, Arumugakani, G, Baker, K, Bahal, S, Baxendale, H, Bermingham, W, Bhole, M, Boules, E, Bright, P, Chopra, C, Cliffe, L, Cleave, B, Dempster, J, Devlin, L, Dhalla, F, Diwakar, L, Drewe, E, Duncan, C, Dziadzio, M, Elcombe, S, Elkhalifa, S, Gennery, A, Ghanta, H, Goddard, S, Grigoriadou, S, Hackett, S, Hayman, G, Herriot, R, Herwadkar, A, Huissoon, A, Jain, R, Jolles, S, Johnston, S, Khan, S, Laffan, J, Lane, P, Leeman, L, Lowe, DM, Mahabir, S, Lochlainn, DJM, McDermott, E, Misbah, S, Moghaddas, F, Morsi, H, Murng, S, Noorani, S, O'Brien, R, Patel, S, Price, A

“...REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. ...”

Deep learning identifies synergistic drug combinations for treating COVID-19 gan Jin, Wengong, Stokes, Jonathan, Eastman, Richard T., Itkin, Zina, Zakharov, Alexey V., Collins, James J., Jaakkola, Tommi S, Barzilay, Regina

“...We empirically validated our model predictions and discovered two drug combinations, remdesivir and reserpine as well as remdesivir and IQ-1S, which display strong antiviral SARS-CoV-2 synergy in vitro. ...”
Cael y testun llawn

Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use' gan Hassan, MZ, Rojek, A, Olliaro, P, Horby, P

“...Current care relies on supportive measures and the ‘compassionate use’ of unapproved drugs like ribavirin and remdesivir. Drugs used ‘off-label’ during outbreaks can become the ‘standard of care’ without robust evidence of their safety or efficacy, complicating the testing of new therapies and perpetuating uncertainty about their true effectiveness. ...”

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment gan Ohashi, H, Watashi, K, Saso, W, Shionoya, K, Iwanami, S, Hirokawa, T, Shirai, T, Kanaya, S, Ito, Y, Kim, KS, Nomura, T, Suzuki, T, Nishioka, K, Ando, S, Ejima, K, Koizumi, Y, Tanaka, T, Aoki, S, Kuramochi, K, Suzuki, T, Hashiguchi, T, Maenaka, K, Matano, T, Muramatsu, M, Saijo, M, Aihara, K, Iwami, S, Takeda, M, McKeating, JA, Wakita, T

“...We screened a panel of already approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as remdesivir and chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug cepharanthine and human immunodeficiency virus protease inhibitor nelfinavir. ...”

COVID-19 Treatment—Current Status, Advances, and Gap gan Chian Ho, Lee, Ping Chin

“...Therapeutic drugs include the FDA-approved antiviral drugs, Remdesivir, and an immune modulator, Baricitinib. Hence, therapeutic approaches and alternatives for COVID-19 treatment need to be broadened. ...”
Cael y testun llawn
Cael y testun llawn